MedPath

Evaluation for efficacy and safety of Angiotensin Converting Enzyme Inhibitor in treatment of proteinuria in cyanotic congenital heart diseases

Phase 2
Conditions
oxygen saturationurine proteinserum creatinine
enalapril&#44
proteinuria&#44
microalbuminuria&#44
cyanotic heart diseases
Registration Number
TCTR20180208003
Lead Sponsor
Faculty of Medicine, Chiang Mai University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending (Not yet recruiting)
Sex
All
Target Recruitment
100
Inclusion Criteria

cyanotic congenital heart diseases with microalbuminuria

Exclusion Criteria

Patients that have contraindicated for enalapril

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
proteinuria 0, 1, 3 month urine protein analysis
Secondary Outcome Measures
NameTimeMethod
renal function 0, 1, 3 month serum Creatinine
© Copyright 2025. All Rights Reserved by MedPath